The artificial intelligence is a great style in cancer treatment, and usually focuses to detect cancer at the earliest stage. That makes a lot of understanding, because the cancer is less dangerous before it is detected.
But fewer thank you another basic question: If someone cancer, as an aggressive treatment like the required chemotherapy? This is a problem of atataraxis AI trying to solve.
Startup is based on the new York has focused to use AI by predicting the accurately not only if the patient has a cancer, but also what cancer do with 10 years. If there is a minor cancer that will return, Chemo can be avoided all – save a lot of money, while avoiding famous side effects.
Ataraxis AI currently plans for the first commercial test, for the breast cancer, for the US oncologist in the coming months, the founder Jan Witewski tells TechCrunki. To join the launch and expand into other cancers, Introduction has returned $ 20.4 million a, they tell techcrunch with exclusive.
Round is led by aix attempts with Fund Thiel Bio, founders, floating point, benthsmann, and a giant investor that exists and a clear effort investor. Ataraxis emerged Of the past year’s stealth with a seed of $ 4 million.
AtataraXis was established with Witowski and Krzysztof and Krzysztof Geras, Krzysztof Geras, teacher assistant in medical school Nyu focused on AI.
Tech Atataraxis is convicted by the AI model who appointed information from high high-resolution cancer cells. The model is trained in hundreds of real-millions of images of the patient, Witowski said. The new research shows the techaraxis’ tech accurate than the current treatment for breast cancer, each attaraxis.
Long-term, ataraxis has a large ambition. Wishing the test to impact at least half of the new cancer cases in 2030. Also see myself as a AI front company that builds a model itself, touting itself Head of Head of AI Scientists Yyann Lexic is a mini advisor.
“I think in Atataraxis, we try to build what is important in the Frontier Lab, but for health applications,” Witowski says. “Because many of these problems require novel technology.”
AI boom has caused rush funds for the start of cancer treatment. Labs Valar Raise $ 22 million To help patients identify the treatment plan on May 2024, for example. There is also a Coman’s Coman Trevenere Ai developed in cancer space, like Manas Ai, who Raising $ 24.6 million in 2025 January And it has founded Hoffman co-reid, who has the couple of the leapery.
